Cipla signs licensing deal with Lilly to sell two diabetes drugs in India
Cipla has signed a licensing deal with the Indian subsidiary of US pharma giant Eli Lilly and Company (Lilly) pertaining to the latter’s diabetes treatments — Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide) in India. In this connection, Lilly will transfer its rights in India to sell, promote, and distribute the two […]